Project Grant R01AI194916
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $553K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Dana-Farber Cancer Institute, Inc. $267,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on integrase-targeted activators of cell death in HIV-1-infected cells. The research assesses the developmental potential of integrase-targeting compounds to induce pyroptotic cell death in HIV-infected cells, building on prior work with reverse-transcriptase-targeting...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $791,065 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into the role of capsid interactions with viral RNA genome in assembly of HIV-1 cores. The research investigates how HIV-1 capsid proteins and viral RNA genome components organize during viral maturation. The study will clarify structural mechanisms underlying HIV-1 core formation,...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $100,228 on November 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). MIT will conduct research examining the molecular basis of T cell allorecognition in graft-versus-host disease and graft-versus-leukemia. The research uses a repertoire-scale examination to determine the molecular mechanisms underlying T cell recognition of non-self major...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded Brandeis University $841,708 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on sulfur-substituted glycoconjugate immunogens designed to elicit broadly-neutralizing antibodies against HIV. The funded research investigates how high-mannose glycans stabilized against mannosidase...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $237,932 on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structural and biochemical studies of HIV and mouse mammary tumor virus (MMTV) retroviral integration onto nucleosome-bound target DNA. The recipient will employ nucleosome reconstitution and sequencing strategies, biochemical binding and activity assays, and high-resolution...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $1,032,783 to Massachusetts General Hospital on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on broadly neutralizing antibodies against HIV. The research, led by Dr. Alejandro Balazs at the Ragon Institute of MGH, MIT & Harvard, focuses on engineering the immune system through gene...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $624,806 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize nanotrap therapeutic vaccines for HIV treatment. The project, titled "Nanotrap Therapeutic Vaccines for HIV Virion Capture and Infected Cell Targeting" (R01AI203404), will engineer liposomal nanoparticles displaying multivalent CD4 mimetic ligands designed to capture...